Article info

Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)

Authors

  1. Correspondence to Professor Maxime Dougados, Hopital Cochin, Rheumatology, Université Paris Descartes, Paris 75014, France; maxime.dougados{at}aphp.fr
View Full Text

Citation

Dougados M, Wei JC, Landewé R On behalf of COAST-V and COAST-W Study Groups, et al
Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)

Publication history

  • Received August 1, 2019
  • Revised October 3, 2019
  • Accepted October 5, 2019
  • First published November 4, 2019.
Online issue publication 
May 11, 2023

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.